Literature DB >> 24577462

The temporospatial evolution of neuritic plaque-related and independent tauopathies: implications for dementia staging.

Donald R Royall1, Raymond F Palmer2.   

Abstract

Neuritic plaque (NP) formation can be dated in vivo. This analysis attempts to "date" the progression of neurofibrillary tangles (NFT) using the spatial distribution of NP as a reference. Autopsy data from 471 participants in the Honolulu-Asia Aging Study (HAAS) were combined into latent factor measures of NFT and NP counts. The variance in "early" and "late" NP pathology was used to estimate the spatial distribution of "early" and "late" NFT formation. A third latent factor representing "non-NP-related NFT" was also constructed. "Early" NP and "late" NP correlated significantly with objectively early and later cognitive performance, respectively. In contrast to our expectations, neocortical NFT correlated best with "early" NP pathology, while NFT in allocortical structures correlated best with "late" NP pathology. Therefore, the NP-related fraction of NFT appears to be co-localized spatially with NP. However, since the latter evolve corticofugally in time, this suggests that NP-related NFT do so as well. Corticotropic NFT formation must therefore be either unrelated to NP formation, a temporally distinct process, or both.

Entities:  

Keywords:  Alzheimer's disease; dementia; mild cognitive impairment; neuropathology

Mesh:

Year:  2014        PMID: 24577462      PMCID: PMC4459125          DOI: 10.3233/JAD-131733

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  31 in total

1.  Latent variables, measurement error and methods for analysing longitudinal binary and ordinal data.

Authors:  M Palta; C Y Lin
Journal:  Stat Med       Date:  1999-02-28       Impact factor: 2.373

2.  Recent clinical-pathologic research on the causes of dementia in late life: update from the Honolulu-Asia Aging Study.

Authors:  Lon White; Brent J Small; Helen Petrovitch; G Webster Ross; Kamal Masaki; Robert D Abbott; John Hardman; Daron Davis; James Nelson; William Markesbery
Journal:  J Geriatr Psychiatry Neurol       Date:  2005-12       Impact factor: 2.680

3.  Characterization of Japanese-American men with a single neocortical AD lesion type.

Authors:  Helen Petrovitch; G Webster Ross; Qimei He; Jane Uyehara-Lock; William Markesbery; Daron Davis; James Nelson; Kamal Masaki; Lenore Launer; Lon R White
Journal:  Neurobiol Aging       Date:  2007-05-17       Impact factor: 4.673

Review 4.  Missing data analysis: making it work in the real world.

Authors:  John W Graham
Journal:  Annu Rev Psychol       Date:  2009       Impact factor: 24.137

5.  Alzheimer neuropathologic alterations in aged cognitively normal subjects.

Authors:  D G Davis; F A Schmitt; D R Wekstein; W R Markesbery
Journal:  J Neuropathol Exp Neurol       Date:  1999-04       Impact factor: 3.685

6.  Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease.

Authors:  V Haroutunian; D P Purohit; D P Perl; D Marin; K Khan; M Lantz; K L Davis; R C Mohs
Journal:  Arch Neurol       Date:  1999-06

7.  Brain lesions at autopsy in older Japanese-American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu-Asia aging study.

Authors:  Lon White
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

8.  Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease.

Authors:  Peter T Nelson; Erin L Abner; Frederick A Schmitt; Richard J Kryscio; Gregory A Jicha; Karen Santacruz; Charles D Smith; Ela Patel; William R Markesbery
Journal:  J Neuropathol Exp Neurol       Date:  2009-07       Impact factor: 3.685

9.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.

Authors:  Clifford R Jack; Val J Lowe; Stephen D Weigand; Heather J Wiste; Matthew L Senjem; David S Knopman; Maria M Shiung; Jeffrey L Gunter; Bradley F Boeve; Bradley J Kemp; Michael Weiner; Ronald C Petersen
Journal:  Brain       Date:  2009-03-31       Impact factor: 13.501

10.  Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.

Authors:  Yi Li; Juha O Rinne; Lisa Mosconi; Elizabeth Pirraglia; Henry Rusinek; Susan DeSanti; Nina Kemppainen; Kjell Någren; Byeong-Chae Kim; Wai Tsui; Mony J de Leon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-20       Impact factor: 9.236

View more
  8 in total

1.  Association of APOE with tau-tangle pathology with and without β-amyloid.

Authors:  Jose M Farfel; Lei Yu; Philip L De Jager; Julie A Schneider; David A Bennett
Journal:  Neurobiol Aging       Date:  2015-09-28       Impact factor: 4.673

Review 2.  18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Authors:  Gabriel Martínez; Robin Wm Vernooij; Paulina Fuentes Padilla; Javier Zamora; Leon Flicker; Xavier Bonfill Cosp
Journal:  Cochrane Database Syst Rev       Date:  2017-11-22

Review 3.  18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Authors:  Gabriel Martínez; Robin Wm Vernooij; Paulina Fuentes Padilla; Javier Zamora; Leon Flicker; Xavier Bonfill Cosp
Journal:  Cochrane Database Syst Rev       Date:  2017-11-22

4.  PART, a distinct tauopathy, different from classical sporadic Alzheimer disease.

Authors:  Kurt A Jellinger; Irina Alafuzoff; Johannes Attems; Thomas G Beach; Nigel J Cairns; John F Crary; Dennis W Dickson; Patrick R Hof; Bradley T Hyman; Clifford R Jack; Gregory A Jicha; David S Knopman; Gabor G Kovacs; Ian R Mackenzie; Eliezer Masliah; Thomas J Montine; Peter T Nelson; Frederick Schmitt; Julie A Schneider; Albert Serrano-Pozo; Dietmar R Thal; Jonathan B Toledo; John Q Trojanowski; Juan C Troncoso; Jean Paul Vonsattel; Thomas Wisniewski
Journal:  Acta Neuropathol       Date:  2015-03-17       Impact factor: 17.088

Review 5.  18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Authors:  Gabriel Martínez; Robin Wm Vernooij; Paulina Fuentes Padilla; Javier Zamora; Xavier Bonfill Cosp; Leon Flicker
Journal:  Cochrane Database Syst Rev       Date:  2017-11-22

6.  Resistance to Alzheimer Disease Neuropathologic Changes and Apparent Cognitive Resilience in the Nun and Honolulu-Asia Aging Studies.

Authors:  Caitlin S Latimer; C Dirk Keene; Margaret E Flanagan; Laura S Hemmy; Kelvin O Lim; Lon R White; Kathleen S Montine; Thomas J Montine
Journal:  J Neuropathol Exp Neurol       Date:  2017-06-01       Impact factor: 3.148

Review 7.  Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. [Corrected].

Authors:  Yan Ma; Shuo Zhang; Jing Li; Dong-Ming Zheng; Yang Guo; Juan Feng; Wei-Dong Ren
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

Review 8.  (11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Authors:  Shuo Zhang; Nadja Smailagic; Chris Hyde; Anna H Noel-Storr; Yemisi Takwoingi; Rupert McShane; Juan Feng
Journal:  Cochrane Database Syst Rev       Date:  2014-07-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.